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Abstract  
Objective 
Linked evidence models are recommended to predict health benefits and cost-effectiveness 
of diagnostic tests. We considered how published models accounted for changes in patient 
pathways that occur with point of care tests (POCTs), and their impact of on patient health 
and costs. 
Study Design and Setting 
Model based evaluations of diagnostic POCTs published from 2004-2017 were identified 
from searching six databases. For each model we assessed the outcomes considered, and 
whether reduced time to diagnosis and increased access to testing affected patient health 
and costs. 
Results 
Seventy-four model based evaluations were included: 95% incorporated evidence on test 
accuracy, but 34% only assessed intermediate outcomes such as rates of correct diagnosis. 
Of 54 models where POCTs reduced testing time, 39% addressed the economic and 37% 
the health benefits of faster diagnosis. No model considered differences in access to tests.  
Conclusions  
Many models fail to capture the effects of POCTs in increasing access, advancing speed of 
diagnosis and treatment, reducing anxiety and the associated costs. Many only consider the 
impact of testing from changes in accuracy. Ensuring models incorporate changes in patient 
pathways from faster and more accessible testing will lead to economic evaluations that 
better reflect the impact of POCTs. 
Keywords:  
Diagnostic test; post of care test; decision model; clinical pathway; health economic model  
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What is new? 
 
 Point of care tests have the potential to speed up decision making, enabling patients to 
access appropriate treatment faster and reduce anxiety waiting for results. 
 Point of care tests can be undertaken in different settings allowing broader access to 
testing. 
 Published model based economic models do not always capture the relevant patient and 
economic benefits of point of care tests, meaning that the conclusions from these models 
may not always be valid. 
 We propose a checklist of considerations that should be made when developing models 
to evaluate the health economic impact of a POCT. 
 Future studies that focus on the clinical and economic evaluation of POCTs should 
ensure that the specific characteristics of these tests are incorporated in the analysis. 
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1 Introduction  
The decision to use a diagnostic test ideally should be based on evidence that it leads to 
better patient outcomes (1), and that improvements from testing are worth any additional 
costs involved. However, there are many logistical obstacles in directly evaluating the impact 
of tests on patient outcomes and their associated cost-effectiveness. There is a dearth of 
trials which randomly allocate participants between alternative testing strategies, evaluate 
resource use arising from testing and subsequent interventions, and compare final outcomes 
at the end of the health care episode (2). Where they do exist, they are often underpowered 
to detect differences in outcomes, potentially biased, and there are challenges in using their 
results to inform practice due to lack of standardization and detail about the test-treatment 
strategies used (3, 4).  
Decision models provide an alternative approach to evaluate the likely effectiveness and 
cost-effectiveness of diagnostic tests. So called linked evidence models combine evidence 
on the performance of each test with evidence of the effectiveness of interventions to predict 
outcomes for each test-treat strategy. They can be used where there is no suitable evidence 
provided by randomised controlled trials (RCTs), and are recommended and routinely used 
by technology assessment organisations included the National Institute for Health and Care 
Excellence (NICE) in the UK (5) and the Agency for Healthcare Research and Quality 
(AHRQ) in the US (6). In their simplest form, models are constructed by estimating the 
proportions of true positives, true negatives, false positives and false negatives for each test 
strategy and assigning likely resource use and outcomes according to the disease state, and 
whether individuals receive appropriate effective treatment (dependent on whether the 
diagnosis is correct). A simplifying assumption is often made, that the management of each 
patient is determined entirely by the test result obtained and both clinicians and patients 
follow through with the recommended treatment. Outcomes such as quality adjusted life 
years (QALYs) are used to capture health benefits, as these allow comparisons of cost-
effectiveness to be made for interventions across different settings (7). They also incorporate 
the unintended harm (8) and adverse events from unnecessary treatments following a false 
positive result, or the impact of continuing to suffer from a disease following a false negative 
test result (9). 
In recent years there has been substantial investment in the development and provision of 
point of care tests (POCTs, also known as rapid tests or near patient tests) that can be 
conducted in close proximity (both in time and in setting) to a patient (10). Examples include 
nucleic acid amplification tests (NAATs) to diagnose tuberculosis (11) and 
immunochromatographic tests (ICT) for the diagnosis of influenza (12).  
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POCTs have the potential to revolutionize care pathways as they produce results more 
quickly than their laboratory counterparts, often allowing patient management to be 
determined in the same consultation when the test is deployed. This may shorten health 
care episodes through removing the time spent waiting for a diagnosis before any 
intervention can commence, and has associated economic benefits in terms of a reduction in 
length of hospital stay, repeat hospital admissions and clinic visits, and reductions in the use 
of interventions for symptom control whilst test results are awaited (13, 14). Faster testing 
could also reduce the costs incurred by patients and carers that fall outside of the healthcare 
system (15) (societal costs), including productivity losses and transport costs.  In some 
conditions, patient outcomes may also be improved by earlier testing, both by avoiding 
deterioration in health (and even death) whilst awaiting test results, or where earlier initiation 
of a treatment may enhance its effectiveness (10, 13). Patients may also experience a 
reduction in anxiety (16) caused by delays in waiting for test results and initiation of 
treatment. In the case of infectious diseases faster testing may reduce disease transmission 
(17).  
POCTs may also change the setting in which testing is undertaken as they are more 
portable than their laboratory equivalents, facilitating their deployment in community or 
primary health care settings rather than in secondary care. This may facilitate testing in 
settings where tests were not previously available. Thus a further perceived benefit of the 
introduction of POCTs is to widen access with more individuals receiving testing, particularly 
in rural areas in low and middle income countries (LMICs).   
The benefits of earlier diagnosis and wider access may mean introduction of a POCT may 
be cost-effective even if it is less accurate and more costly than current practice (18).  
However, creating a decision model that fully captures the benefits of a faster and more 
accessible test requires incorporation of information about the likely difference in the timing 
of diagnosis on resource use, the effectiveness of earlier treatment on patient outcomes, and 
differences in the size and characteristics of the cohorts being tested.  
In this review we evaluated published model based economic evaluations of POCTs to 
assess how evaluations have considered the impact of test timing and access to testing 
alongside differences in accuracy associated with the introduction of POCTs.  
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2 Methods  
We identified recent model based published economic evaluations of POCTs, assessed the 
structure of their models, the parameters that they include and their outcomes, to identify 
whether they have appropriately considered the impact and costs of using a POCT.   
2.1 Search strategy 
Published reports of model based economic evaluations of point of care diagnostic tests 
were identified by searching electronic databases. Medline, Embase and PsycINFO, 
CINAHL, NHS Economic Evaluation Database (NHS EED) and Health Economic Evaluation 
Database (HEED) were searched in October 2017. Search strategies were developed based 
on validated algorithms for identifying health economic evaluations (19) and strings were 
used for the identification of POCTs in the published literature. Supplementary searches 
were conducted based on technical terms or proprietary names of tests found in the original 
searches, and on the bibliographies of included studies. We restricted the search to English 
language articles published between 2004 and 2017 with the aim to understand methods 
currently used when conducting economic evaluations of POCT technologies. Search 
strategies are provided in the Appendix. 
2.2 Inclusion Criteria 
Evaluations were included if they used a model based approach, were reported in a 
published manuscript, considered patients presenting with a specific complaint, signs or 
symptoms, and where at least one strategy involved a POCT (defined as a test performed 
near the patient or treatment facility with a fast turnaround time and may lead to a change in 
patient management) (10). We also included evaluations of accelerated laboratory tests that 
claimed similar changes to testing timeframes. The review was not restricted to any specific 
clinical specialities. We focused on diagnostic tests, and thus excluded studies that 
considered monitoring and screening tests.  We excluded models which focused entirely on 
estimating clinical impact and did not include any economic component. 
2.3 Selection of Articles 
Titles and abstracts were screened for inclusion by one reviewer. Full text copies were 
retrieved for articles meeting the inclusion criteria or those providing insufficient information 
in the abstract to determine their eligibility. A second reviewer independently assessed 
articles that still did not clearly satisfy the inclusion criteria. Excluded articles and reasons for 
their exclusion were documented. 
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2.4 Data Extraction, Analysis and Reporting 
A data extraction form was developed and piloted on a selection of articles and modified 
accordingly. We extracted data to document the inclusion of test accuracy, impact of faster 
testing on patient outcomes, impact of faster testing on costs, the effectiveness measure, the 
perspective for the costs adopted, and difference in setting and participants included for 
each strategy. Data were extracted by one author and checked by a second. We report the 
proportions of economic evaluations that demonstrate each characteristic.   
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3 Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Our search identified 10,302 unique articles, of which 343 were considered potentially 
eligible and reviewed in detail.  In total, 74 model based economic evaluations were 
identified as meeting our inclusion criteria (Figure 1). Evaluations covered diverse clinical 
conditions and were undertaken in primary care, hospital care and the community settings. 
17,841 articles identified by the search 
strategy 
NHS EED 169, Medline 8,324, 
Embase 8,299, PsychInfo 83, CINAHL 
849, HEED 117 
10,302 titles and abstracts screened for 
eligibility 
343 full-text articles assessed for 
eligibility 
7,539 duplicates removed 
9,930 excluded based on title 
and abstract 
22 additional duplicates 
identified 
7 no abstracts or full texts 
available  
60 articles eligible for review 
283 full-text articles excluded 
12 articles identified searching 
by test name or identified from 
other sources 
2 identified through bibliography 
checking 
 74 articles included in review 
Figure 1 Flow Chart Demonstrating Selection of Papers 
Page 9 of 38 
 
There were multiple evaluations of tests for the diagnosis of tuberculosis, malaria and 
influenza (Table 1).  
Studies predominantly assessed the cost-effectiveness of implementing tests in Africa 
(31%), North America (24%) and Europe (22%). Twenty-four (32%) analyses were from the 
perspective of a LMIC country. Only one study evaluated a hypothetical test for tuberculosis 
(20), all others evaluated commercially available tests. 
Table 1 Characteristics of Model Based Economic Evaluations 
 Total (N=74) LMIC 
Indication N (%*) Yes (N=24) No (N=50) 
   N (%) N (%) 
Tuberculosis  24 (32) 10 (42) 14 (28) 
Malaria 13 (18) 11 (46) 2 (4) 
Influenza 11 (15) 0 (0) 11 (22) 
Pharyngitis 4 (5) 0 (0) 4 (8) 
Pulmonary embolism 3 (4) 0 (0) 3 (6) 
Deep vein thrombosis 3 (4) 0 (0) 3 (6) 
Dyspepsia 3 (4) 0 (0) 3 (6) 
Sepsis 2 (3) 1 (4) 1 (2) 
Acute coronary syndrome 2 (3) 1 (4) 1 (2) 
Respiratory tract infection 1 (1) 0 (0) 1 (2) 
Acute myocardial 
infarction  1 (1) 
 
0 
 
(0) 
 
1 
 
(2) 
C-difficile 1 (1) 0 (0) 1 (2) 
Chlamydia and 
gonorrhoea 1 (1) 
 
0 
 
(0) 
 
1 
 
(2) 
Conjunctivitis 1 (1) 0 (0) 1 (2) 
Staphylococci infection 1 (1) 0 (0) 1 (2) 
Staphylococcus aureus 
bacteraemia 1 (1) 
 
0 
 
(0) 
 
1 
 
(2) 
Visceral leishmaniasis 1 (1) 1 (0) 0 (0) 
Meningococcal disease 1 (1) 0 (0) 1 (2) 
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3.1 Effectiveness outcomes 
The majority of models used measures of patient health in the primary analysis (65%): 22 
(30%) reported Quality Adjusted Life Years (QALYs) (1 LMIC country), 11 (15%) Disability 
adjusted life years (DALYs) (9 LMIC countries), and a further 9 (12%) used mortality 
measures (6 LMIC countries) (Table 2). Twenty-five analyses (34%) (8 LMIC countries) 
focused on intermediate outcomes related to test results, diagnoses or treatment.  
Evaluations of tests for infectious diseases also considered markers of disease spread. 
Table 2 Effectiveness Outcomes in Primary Analysis of Model Based Economic Evaluations 
  Outcome used  
N=74 
 
N % 
QALYs / QALDs /DALYs/ Quality adjusted survival 35 (47) 
Deaths averted/life years saved or lost/death from target 
indication/cure without complications/symptom free days 
or years 
13 (18) 
Infections prevented* 1 (1) 
Correct diagnosis/correct treatment/positive test/false 
positives/patients treated/ work productivity gained * 
25 (34) 
Quality adjusted life years (QALYs), Quality adjusted life days (QALDs), Disability adjusted 
life years (DALYs) 
*Intermediate outcomes not demonstrating a direct health benefit 
 
3.2 Cost perspective 
The majority of the models that considered the impact of POCT on cost used a healthcare 
payer perspective (17/21) (21-38) and one model reported results using both a payer and 
societal perspective (39). The remaining three models reported a societal perspective only 
(40-42). 
3.3 Test accuracy and diagnostic errors 
Seventy of the 74 (95%) models considered test accuracy and 51 studies considered how 
varying test accuracy in sensitivity analysis would impact on the conclusions drawn from the 
analyses. Incorrect and failed tests can have implications for patient health and costs and 57 
models addressed these issues. Unnecessary harms, such as adverse events from 
inappropriate treatment were estimated in 17 studies (23, 28, 31, 43-56), and the cost of 
treating a false positive or false negative patient in seven (33, 57-62). Three models adjusted 
mortality rates (63-65) and five cost utility analyses adjusted utilities due to the untreated 
disease state (24, 48, 54, 57, 61). The risk of transmission as a result of an incorrect 
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diagnosis was incorporated in four infectious disease models (60, 62, 66, 67), as was test 
failure (30, 34, 68, 69). The need for retesting after an incorrect result was considered in one 
study (70). 
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3.4 Effects of Faster Testing 
The effects of timing of tests were judged of importance in 54 of the 74 models. The effects 
of diagnostic timing were not relevant in 20 studies (27%) (45, 46, 48-50, 54, 56, 67, 71-82), 
where the POCT could not affect the speed of treatment compared to the alternative 
strategy, for example, when the only comparator was presumptive treatment or no test. 
These were predominantly economic evaluations of malaria or tuberculosis tests. 
Only 29 studies (20, 23, 24, 26-37, 41, 43, 44, 57, 58, 60, 62, 65, 69, 83-87) incorporated 
the aspect of time to diagnosis in the model. Thus, some aspect of the benefits of quicker 
test results were incorporated in just over half (54%; 29/54) of the models where it was of 
relevance (see Web Table 4 for description of how the 29 models incorporated time to 
diagnosis in terms of patient impact and/or costs). 
Twenty models (37%) captured the impact of faster testing on patient outcomes: three by 
quicker resolution of disease (dyspepsia (43), pharyngitis (28, 84)); four through reductions 
in disease progression or reduced mortality (chlamydia and gonorrhoea progressing to pelvic 
inflammatory disease (35), mortality from sepsis (36), mortality from tuberculosis (24, 37)); 
seven from increases in the numbers starting treatment through reductions in loss to follow-
up (all tuberculosis (23, 27, 29, 30, 34, 62, 69)); three from reductions in harms through 
reduced use of presumptive treatment (chlamydia and gonorrhoea (35), clostridium difficile 
infection (33), pharyngitis (44)), and one from reduced anxiety whilst waiting for results 
(chlamydia and gonorrhoea (35)). Two reduced QALYs to reflect the disutility of time in 
intensive care (36, 87).  
Twenty-one models (39%) incorporated the impact of implementing a POCT on costs.  Cost 
advantages for POCT arose from fewer visits to healthcare providers to receive results, less 
clinician time to conduct the test and shorter length of stay due to faster decision making and 
treatment initiation (23, 24, 26, 28-36, 41, 44, 60, 83, 84, 87). Reduced treatment or testing 
costs were observed as a result of avoiding presumptive treatment, additional tests and the 
need to treat disease which had progressed (24, 26, 27, 31, 33, 35, 37, 41, 43, 44, 87). 
Three models incorporated the time taken for testing, but it was unclear from the model 
descriptions how this would impact on costs or patient outcomes (20, 58, 65).  
Figure 2 summarises how frequently the economic models considered faster testing in the 
analysis. ‘Included in model’ refers to any economic or patient impact parametrised in the 
model. Patient impact includes more effective earlier treatment, earlier treatment initiation 
and duration of illness reduced. Harms from unnecessary or inappropriate treatment are also 
incorporated, as are anxiety during the diagnostic delay and reduced disease progression. 
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Impact on operational costs refers to costs incurred when delivering treatment or testing 
procedures, such as clinical consultations or residing in hospital. 
 
Figure 2 Frequency of the consideration of the effects of faster testing in the 54 model 
based economic evaluations where timing of tests differed between strategies compared 
(Included in model indicates that any difference in outcome or cost was considered). 
 
3.5 Costs of the test-treatment pathway 
Twenty-five studies included societal costs in the economic evaluation. In the case of 
influenza, antiviral treatment guided by rapid testing reduced symptom duration and 
productivity losses for patients or their carers were considered (45-48, 50, 67, 73), while in 
one tuberculosis study income loss was reduced as a result of fewer days of hospitalization 
waiting for smear/culture results (60). Other costs borne by patients and captured in the 
analyses included loss of income related to the duration of their clinic visit (40, 88)   and 
travel costs (52, 60, 72, 89-91). The costing of productivity loss could enhance the cost-
effectiveness of the POCTs, although in 85% of studies this was omitted. The majority of 
models included the cost of one course of treatment, such as antimalarials or antibiotics. 
Costs of treating complications from unresolved illnesses or adverse events were frequently 
included. A minority (5%) did not include any costs beyond the testing procedure (68, 92-94). 
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3.6 Access to testing 
The introduction of a POCT changed the location of testing in eight models (26, 28, 41, 53, 
72, 85, 89, 91) (Table 3). This was predominantly a move from secondary to primary care 
settings, with one model examined the provision of testing in a pharmacy setting (28).  
Twenty-four analyses included a comparator arm of either presumptive treatment or no test. 
Of these, nine (46, 49, 50, 52, 76, 78, 79, 81, 82) did not include any slower testing method 
and therefore modelled a situation where testing was previously unavailable. In total, 11 
(45.8%) economic evaluations conducted from the perspective of LMICs analysed the 
impact of introducing a test where current practice could result in a patient receiving no 
diagnostic test (49, 51-53, 71, 79, 81, 82, 89, 90, 95).    
All models assumed that the same patient group would follow through each of the strategies 
considered; there was no allowance made in the POCT arms for inclusion of additional 
patients who access standard laboratory testing. 
      
Table 3 Impact of POCT on Access to Testing 
  
Total (N=74) 
 
LMIC 
N (%) 
Yes (N=24) No (N=50) 
N (%) N (%) 
Change in geographical 
location (e.g. primary to 
secondary care) 
8 (11) 3 (13) 5 (10) 
Access 
to 
testing 
Yes (slower test 
and no 
test/presumptive 
treatment) 
15 (20) 6 (25) 9 (18) 
Yes (no test 
alternative) 
9 (12) 5 (21) 4 (8) 
Tested a different 
population 
0 (0) 0  0 (0) 
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4. Discussion 
Introduction of a POCT into a diagnostic pathway can substantially change diagnostic and 
treatment pathways, altering who is tested, when and where testing is done, when treatment 
can commence, and the health care resources, staff and equipment required.   These 
changes impact on patient pathways, potentially changing patient outcomes.   
In this review of recently published economic evaluations we found that many economic 
models evaluating POCT strategies failed to capture the key routes by which POCTs may 
create patient benefit and change resource use. In the models where there was a difference 
in timing of diagnosis between strategies, only 37% considered possible health benefits and 
39% considered differences in resource use arising from reducing the time to diagnosis 
through switching to a faster test.   There were no evaluations which considered how POCT 
availability and access may increase numbers undergoing testing. 
In contrast, 95% of the reviewed models considered the impact of differences in accuracy, 
(higher than the 63% of cost-utility analyses of laboratory tests reviewed by Fang et al (8)). 
As point of care tests may have inferior accuracy compared to their laboratory based 
equivalents, it is important that any increase in false positive and false negative diagnoses 
through reduced accuracy is included in a decision model. Incorrect test results can have 
implications on costs, patient outcomes, affect disease transmission, and delay the 
diagnosis of other serious conditions, thus justifying their importance in analyses (96).  
However, where differences in accuracy are small, the greatest impact on outcomes and 
resource use is likely to occur from differences in the diagnostic and treatment pathways.  
Around half the models reported utility based outcomes, such as the QALY, DALY and 
QALD. NICE (97) and The World Health Organisation Choosing Interventions that are Cost 
Effective (WHO-CHOICE) (98) project recommend the QALY and the DALY as effectiveness 
outcomes respectively as they allow incorporation of patient benefits and harms into a single 
metric. It is encouraging that these standardised measures are being used as the value of 
these tests can be assessed in comparable terms to treatments and other health 
technologies. However the appropriateness of an outcome predominantly composed of 
length of life for capturing benefits and harms in a testing situation is debatable. For 
example, how comparable are 10,000 patients waiting less time for a test result and 
increasing life expectancy of four patients by six months? Only one study addressed the 
psychological impact of waiting for test outcomes. When comparing a rapid test to a slower 
comparator, omitting a utility decrement or other methodology that captures anxiety 
experienced due to delay might not truly reflect the incremental benefit of a rapid test. 
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Intermediate outcomes related to tests or interventions were reported as the primary 
outcome in 32% of studies. In some circumstances these endpoints may be appropriate as 
surrogates for patient benefits, but they fail to consolidate the multiple ways in which tests 
impact on patients into a single measure. A minority of studies only considered the cost of 
the test and not the test-treatment pathway. As the intention of testing is to inform patient 
management and improve their health, these models fail to capture the true economic and 
health implications of the testing pathway.  
Two thirds of models excluded costs incurred by patients, their carers and any impacts on 
productivity. The omission of these costs may be a consequence of adopting the perspective 
recommended by the target decision maker. In the UK, NICE (97) recommend that only 
costs borne by the NHS and personal social services are included. In contrast The 
Netherlands prescribe a societal perspective, to include costs of patient’s time (leisure time 
and paid/unpaid work) and travel. Adhering to these guidelines limits the transferability of the 
results, yet may be an unavoidable consequence. Excluding societal costs may particularly 
undervalue POCT technologies as they typically provide savings to patients through 
reductions in time spend in contact with health services. 
A previous evaluation considered models for evaluating POCT tests for tuberculosis (99). 
Challenges identified included uncertainties regarding transmission relative to time of 
diagnosis, treatment initiation and loss to follow-up. The ability of the health system to inform 
patients of test results and the timely initiation of treatment were described in some 
transmission and health system models, although not those evaluating cost-effectiveness 
(99). Similar to our findings; the cost-effectiveness models failed to model the full test 
treatment pathway and omitted patient incurred costs. As tuberculosis is a disease 
associated with poverty, patient costs could prove a barrier to testing. Drain et al proposed a 
specification (100) for an ideal evaluation of point of care tests for use in resource limited 
settings, suggesting a shift in emphasis from test accuracy to outcomes such as time to 
treatment initiation or patient notification rate. In resource limited settings clinical benefit from 
expediting decision making may be of greater value than test accuracy.   
Evaluating the impact of a test strategy that substantially changes diagnostic and treatment 
pathways, potentially leading to increased access to testing and subsequent healthcare is 
challenging.  A primary assumption made in the all the decision models considered is that 
the hypothetical cohort of patients  in the model can all follow each of the strategies being 
compared.  In reality this is unlikely to be the case when a POCT is introduced, particularly 
when the POCT allows testing in a different healthcare setting. For example, the models 
considering testing for malaria typically compare strategies of treatment based on results of 
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POCT with a strategy of treatment based on microscopy (laboratory) testing.  They do not 
include patients who in reality would receive a POCT if available, but could never have 
access to microscopy – who potentially would receive either empirical treatment or no 
treatment at all.  Future models could consider incorporation of comparative strategies which 
include a realistic mixture of alternative pathways.  
We believe that there are two main reasons why the omissions in economic evaluations for 
POCTs described in our review occur. First, there is lack of awareness of the routes by 
which tests impact on patients beyond test accuracy. Many courses, guides and textbooks 
on test evaluation solely focus on sensitivity, specificity and other measures of test accuracy. 
Recently a framework of mechanisms by which tests impact on patients was published 
based on a review of over 100 clinical testing scenarios evaluated in randomised controlled 
trials (101). The framework identified issues related to testing timeframes as key 
mechanisms for creating patient benefit, alongside accurate and confident decision-making, 
and reducing the direct harms of testing. We would recommend using the checklist that 
accompanies this framework when scoping models for test scenarios. Second are the 
challenges in obtaining estimates of the parameters required to create a decision model that 
factors in the impact of changing time frames and setting on patient outcomes and costs. 
There may often be a lack of empirical evidence upon which to base parameter estimates, 
while expert judgement and sensitivity analyses may also be required. As a minimum, 
authors should acknowledge the limitations of their models and simplifications that have 
been made where they do not fully represent the reality of how POCTs impact on patients 
and costs. We have developed a set of considerations that could be consulted during the 
development of economic models of POCTs (Figure 3). These address key issues we have 
identified that will enable the development of models that adequately capture both patient 
related outcomes and cost implications of these technologies. Whilst not all items will be 
relevant to every test, we hope these will address the inadequacies this review has 
highlighted. 
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Figure 3 Proposed Considerations During Model Development 
 
There are a number of limitations to the current study. We restricted searches to the last 13 
years, and our searches will inevitably have missed some eligible economic evaluations, 
both those in non-English language journals and those which use different terminology than 
that included in our electronic search. A database of test names or additional terminology not 
used in original searches was developed during abstract screening and supplementary 
Extra Considerations When Modelling the Cost-Effectiveness of 
POCTS 
 
Patient and process related outcomes 
Does a difference in test setting or time to diagnosis and treatment impact on: 
1. Who will be tested 
2. Survival to the start of treatment 
3. The health state at the start of treatment / disease progression  
4. Effectiveness of treatment (e.g. survival following the initiation of treatment / time 
to symptom resolution) 
5. Psychological harms (e.g. anxiety waiting for results) 
6. Time in poor health before treatment 
7. Harms of inappropriate treatment 
8. Patients lost to follow-up / not commencing treatment 
9. Disease spread (infectious diseases only) 
Resource use (costs) and changes to the diagnostic pathway 
Does using a POCT change: 
1. Numbers being tested (e.g. access in resource limited settings)  
2. Use of empiric/presumptive therapy  
3. Clinician time to administer tests 
4. Individuals able to administer tests 
5. Number of healthcare consultations (e.g. receipt of results) 
6. Logistic requirements for testing, delivery and storage (e.g. refrigeration) 
7. Training requirements 
8. Costs incurred by patients (e.g. work productivity, transport) 
Test characteristics 
1. Differences in the number of true positives/false negatives (sensitivity: the 
percentage with target condition who receive the right diagnosis) 
2. Differences in the number of true negatives/false positives (specificity: percentage 
without target condition who get right diagnosis) 
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searches were subsequently conducted. However, we would not expect the models we have 
missed to be qualitatively different than those we have evaluated. It is possible that study 
reports failed to fully report their models as a consequence of space limitations, and omitted 
information about pertinent costs or outcomes. We noted relevant information in appendices 
for some reports suggesting this information may be perceived as less critical to report.  A 
benefit of POCTs unrelated to delay and not investigated in this review is the reduction in 
secondary tests required. This is an important feature of any new test, improving the testing 
process for patients and reducing resource use. How POCTs influence the number of tests 
patients undergo and the cost implications could also be investigated further.  
5. Conclusion 
This study has shown that many published economic evaluations of POCTs have failed to 
capture the advantages of increased access and speed to diagnosis and treatment on 
patient outcomes, and the reductions in patient anxiety and cost that can affect both the 
health services and patients themselves. We therefore suggest that more should be done to 
ensure that the methods used in model based economic evaluations of POCTs adequately 
consider the impact POCTs have on diagnostic and treatment pathways through changes in 
testing setting and timing. 
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Web Table 3  Model Inputs Capturing Effect of Time to Diagnosis 
Reference Indication 
Impact on patients 
N=20 (37%)* 
Impact on test or 
treatment costs 
N=8 (15%)* 
Impact on 
operational costs 
N=19 (35%)* 
Faster testing 
described in 
model inputs  
N=4 (7%) 
Perspective of 
economic evaluation 
Societal N=4 (14%) 
Societal/payer N= 2 
(7%) 
Payer N =  23 (79%) 
Kip (41) Acute coronary 
syndrome 
  Hospitalisation 
costs** 
 Societal 
Jancovic (26) Acute coronary 
syndrome 
 Additional tests ** Hospital referral** 
 
 Healthcare payer 
Turner (35) Chlamydia and 
gonorrhoea 
Pelvic inflammatory 
disease 
Anxiety whilst waiting 
Harms of presumptive 
treatment 
Pelvic inflammatory 
disease treatment** 
Presumptive 
treatment*  
Clinician time** 
Clinic visits*** 
 Healthcare payer 
Schroeder (33) Clostridium 
difficile 
infection   
Harms of presumptive 
treatment 
Presumptive 
treatment**  
Pre-emptive 
isolation**  
Laboratory 
technician time** 
Reagents** 
 Healthcare payer 
Fauli  (43) Dyspepsia Symptom free days  Healthcare 
consultations*** 
 Societal 
Nelson (31) Influenza  Empiric treatment** 
Additional tests** 
Laboratory 
technician time** 
 Healthcare payer 
You (38) Influenza QALY loss in ICU 
Illness duration 
 Clinic visits** 
ICU utilisation** 
 Healthcare payer 
Alonso (23) Leishmaniasis Time to treatment 
initiation 
 Hospitalisation 
costs** 
 Healthcare payer 
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Reference Indication 
Impact on patients 
N=20 (37%)* 
Impact on test or 
treatment costs 
N=8 (15%)* 
Impact on 
operational costs 
N=19 (35%)* 
Faster testing 
described in 
model inputs  
N=4 (7%) 
Perspective of 
economic evaluation 
Societal N=4 (14%) 
Societal/payer N= 2 
(7%) 
Payer N =  23 (79%) 
Giraldez-Garcia, 
(44) 
Pharyngitis Harms of presumptive 
treatment  
Presumptive 
treatment** 
Clinic visits*** 
Telephone 
consultations*** 
 Healthcare payer 
Howe (84) Pharyngitis Time to symptom 
resolution (QALDs)**** 
 Telephone 
consultations*** 
 Healthcare payer and 
societal 
Klepser (28) Pharyngitis Time to symptom 
resolution (QALDs)**** 
 Telephone 
consultations*** 
 Healthcare payer 
Ward (36) Sepsis Mortality 
Earlier resuscitation 
Disutility of ICU stay 
 ICU utilisation**  Healthcare payer 
 
Dowdy, Lourenco 
(57) 
Tuberculosis DALYs averted     Healthcare payer 
Schnippel, Meyer-
Rath (69) 
Tuberculosis Appropriate treatment 
Loss to follow-up 
Diagnoses within one 
week  
   Healthcare payer 
Choi, Miele (24) Tuberculosis Mortality Empiric treatment** Hospitalisation 
costs**  
 Healthcare payer 
Albert (83) Tuberculosis    Clinic visits***  Healthcare payer 
Vassall, 
Kampen(65) 
Tuberculosis   
 
  Turnaround 
times for all 
test strategies 
reported, but 
no impact on 
transmission or 
mortality 
assumed 
Healthcare payer 
Page 23 of 38 
 
Reference Indication 
Impact on patients 
N=20 (37%)* 
Impact on test or 
treatment costs 
N=8 (15%)* 
Impact on 
operational costs 
N=19 (35%)* 
Faster testing 
described in 
model inputs  
N=4 (7%) 
Perspective of 
economic evaluation 
Societal N=4 (14%) 
Societal/payer N= 2 
(7%) 
Payer N =  23 (79%) 
Scherer (60) Tuberculosis    Hospitalisation 
costs** 
Patients’ loss of 
income** 
 Societal 
Menzies (62) Tuberculosis Loss to follow-up     Healthcare payer 
Rajalahti (32) Tuberculosis    Inpatient days** 
Unnecessary 
isolations** 
 Healthcare payer 
Dowdy (58) Tuberculosis    Time to 
diagnosis and 
loss to follow-
up reported  
Healthcare payer and 
societal 
Dowdy (20) Tuberculosis    Time to 
diagnosis and 
loss to follow-
up reported 
Healthcare payer 
Langley (29) Tuberculosis Time to treatment 
initiation Loss to follow-
up 
Treatment completion  
 Clinic visits** Transmission 
whilst waiting 
for treatment 
initiation not 
explicitly 
described 
Healthcare payer 
Meyer-Rat (30) Tuberculosis Loss to follow-up  Clinic visits**  Healthcare payer 
Khaparade (27) Tuberculosis Loss to follow-up 
 
Presumptive 
treatment** 
  Healthcare payer 
Suen (86) Tuberculosis Time to treatment 
initiation 
   Societal 
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Reference Indication 
Impact on patients 
N=20 (37%)* 
Impact on test or 
treatment costs 
N=8 (15%)* 
Impact on 
operational costs 
N=19 (35%)* 
Faster testing 
described in 
model inputs  
N=4 (7%) 
Perspective of 
economic evaluation 
Societal N=4 (14%) 
Societal/payer N= 2 
(7%) 
Payer N =  23 (79%) 
Tesfaye (34) Tuberculosis Loss to follow-up 
Treatment completion 
Time to treatment 
initiation 
 Clinic visits** 
Clinician time ** 
 Healthcare payer 
Oxlade (85) Tuberculosis Time to treatment 
initiation 
   Healthcare payer 
You (37) Tuberculosis Mortality  
with treatment delay 
Presumptive 
treatment** 
  Healthcare payer 
 * Percent of studies where time is relavent **Reduced costs as a result of using POCT ***Increased costs due to slower comparator **** Measured as Quality 
adjusted life days (QALDs)
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Appendix  Search Strategies 
A1 MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to 
Present Search Strategy 
 
 
1 Economics/  
2 exp "costs and cost analysis"/  
3 Economics, Dental/  
4 exp economics, hospital/  
5 Economics, Medical/  
6 Economics, Nursing/  
7 Economics, Pharmaceutical/  
8 (economic$ or cost or costs or costly or costing or price or prices or pricing or 
pharmacoeconomic$).ti,ab. 
 
9 (expenditure$ not energy).ti,ab.  
10 value for money.ti,ab.  
11 budget$.ti,ab.  
12 or/1-11  
13 ((energy or oxygen) adj cost).ti,ab.  
14 (metabolic adj cost).ti,ab.  
15 ((energy or oxygen) adj expenditure).ti,ab.  
16 or/13-15  
17 12 not 16  
18 ("point of care" or "POC test*" or POCT or "near patient" or "desktop technology" or 
"office laboratory" or "set test*").ti,ab. 
 
19 ((test* or diagnos* or assay* or culture* or laborator* or detect* or assess* or identif* 
or evaluat* or marker* or biomarker*) adj3 (rapid* or quick* or fast* or ancillary* or 
bedside* or decentralise* or "patient focus*" or portable*)).ti,ab. 
 
20 exp Point-of-Care Systems/  
21 18 or 19 or 20  
22 17 and 21  
23 letter.pt.  
24 editorial.pt.  
25 23 or 24  
26 22 not 25  
27 exp animals/ not humans/  
28 26 not 27  
29 limit 28 to yr="2004-Current"  
30 limit 29 to english language  
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A2 Embase Classic+Embase (via Ovid) 
 
1 Health economics/ 
2 exp Economic evaluation/ 
3 exp health care cost/ 
4 pharmacoeconomics/ 
5 1 or 2 or 3 or 4 
6 (econom$ or cost or costs or costly or costing or price or prices or pricing or 
pharmacoeconomic$).ti,ab. 
7 (expenditure$ not energy).ti,ab. 
8 (value adj2 money).ti,ab. 
9 budget$.ti,ab. 
10 6 or 7 or 8 or 9 
11 5 or 10 
12 (metabolic adj cost).ti,ab. 
13 ((energy or oxygen) adj cost).ti,ab. 
14 ((energy or oxygen) adj expenditure).ti,ab. 
15 12 or 13 or 14 
16 11 not 15 
17 ("point of care" or "POC test*" or POCT or "near patient" or "desktop technology" or 
"office laboratory" or "set test*").ti,ab. 
18 ((test* or diagnos* or assay* or culture* or laborator* or detect* or assess* or identif* or 
evaluat* or marker* or biomarker*) adj3 (rapid* or quick* or fast* or ancillary* or 
bedside* or decentralise* or "patient focus*" or portable*)).ti,ab. 
19 exp Point-of-Care Systems/ 
20 17 or 18 or 19 
21 16 and 20 
22 letter.pt. 
23 editorial.pt. 
24 note.pt. 
25 22 or 23 or 24 
26 21 not 25 
27 animal/ 
28 exp animal experiment/ 
29 nonhuman/ 
30 (rat or rats or mouse or mice or hamster or hamsters or animal or animals or dog or 
dogs or cat or cats or bovine or sheep).ti,ab,sh. 
31 27 or 28 or 29 or 30 
32 exp human/ 
33 human experiment/ 
34 32 or 33 
35 31 not (31 and 34) 
36 26 not 35 
37 conference abstract.pt. 
38 36 not 37 
39 limit 38 to yr="2004-Current" 
40 limit 39 to english language 
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A3 CINAHL Plus 
#  Query  Limiters/Expanders  
S29  S23 AND S28  Limiters - Published Date: 
20040101-20141231; English 
Language  
Search modes - Boolean/Phrase  
S28  S24 or S25 or S26 or S27  Search modes - Boolean/Phrase  
S27  (MM "Point-of-Care Testing")  Search modes - Boolean/Phrase  
S26  AB ((test* or diagnos* or assay* or culture* or 
laborator* or detect* or assess* or identif* or 
evaluat*) N3 (rapid* or quick* or fast* or ancillary* 
or bedside* or decentralise* or "patient focus*" or 
portable*))  
Search modes - Boolean/Phrase  
S25  TI ((test* or diagnos* or assay* or culture* or 
laborator* or detect* or assess* or identif* or 
evaluat*) N3 (rapid* or quick* or fast* or ancillary* 
or bedside* or decentralise* or "patient focus*" or 
portable*))  
Search modes - Boolean/Phrase  
S24  TI ("point of care" or "POC test*" or POCT or "near 
patient" or "desktop technology" or "office 
laboratory" or "set testing") OR AB ("point of care" 
or "POC test*" or POCT or "near patient" or 
"desktop technology" or "office laboratory" or "set 
testing")  
Search modes - Boolean/Phrase  
S23  S20 not (S21 or S22)  Search modes - Boolean/Phrase  
S22  (ZT "doctoral dissertation") or (ZT "masters 
thesis")  
Search modes - Boolean/Phrase  
S21  MH "animal studies"  Search modes - Boolean/Phrase  
S20  S15 not S19  Search modes - Boolean/Phrase  
S19  S16 OR S17 OR S18  Search modes - Boolean/Phrase  
S18  PT commentary  Search modes - Boolean/Phrase  
S17  PT letter  Search modes - Boolean/Phrase  
S16  PT editorial  Search modes - Boolean/Phrase  
S15  S13 OR S14  Search modes - Boolean/Phrase  
S14  TI (cost or costs or economic* or 
pharmacoeconomic* or price* or pricing*) OR AB 
(cost or costs or economic* or 
pharmacoeconomic* or price* or pricing*)  
Search modes - Boolean/Phrase  
S13  S9 OR S12  Search modes - Boolean/Phrase  
S12  S10 OR S11  Search modes - Boolean/Phrase  
S11  MH "health resource utilization"  Search modes - Boolean/Phrase  
S10  MH "health resource allocation"  Search modes - Boolean/Phrase  
S9  S3 not S8  Search modes - Boolean/Phrase  
S8  S4 OR S5 OR S6 OR S7  Search modes - Boolean/Phrase  
S7  MH "Business+"  Search modes - Boolean/Phrase  
S6  MH "financing, organized+"  Search modes - Boolean/Phrase  
S5  MH "financial support+"  Search modes - Boolean/Phrase  
S4  MH "Financial management+"  Search modes - Boolean/Phrase  
S3  MH "Economics+"  Search modes - Boolean/Phrase  
S2  MH "Financial Management+"  Search modes - Boolean/Phrase  
S1  MH "Economics+"  Search modes - Boolean/Phrase  
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A4 PsycINFO 
1 "costs and cost analysis"/ 
2 "cost containment"/ 
3 (economic adj2 evaluationS).ti,ab. 
4 (economic adj2 analy$).ti,ab. 
5 (economic adj2 (study or studies)).ti,ab. 
6 (cost adj2 evaluation$).ti,ab. 
7 (cost adj2 analy$).ti,ab. 
8 (cost adj2 (study or studies)).ti,ab. 
9 (cost adj2 effective$).ti,ab. 
10 (cost adj2 benefit$).ti,ab. 
11 (cost adj2 utili$).ti,ab. 
12 (cost adj2 minimi$).ti,ab. 
13 (cost adj2 consequence$).ti,ab. 
14 (cost adj2 comparison$).ti,ab. 
15 (cost adj2 identificat$).ti,ab. 
16 (pharmacoeconomic$ or pharmaco-economic$).ti,ab. 
17 or/1-16 
18 (task adj2 cost$).ti,ab,id. 
19 (switch$ adj2 cost$).ti,ab,id. 
20 (metabolic adj cost).ti,ab,id. 
21 ((energy or oxygen) adj cost).ti,ab,id. 
22 ((energy or oxygen) adj expenditure).ti,ab,id. 
23 or/18-22 
24 (animal or animals or rat or rats or mouse or mice or hamster or hamsters or dog or 
dogs or cat or cats or bovine or sheep or ovine or pig or pigs).ab,ti,id,de. 
25 editorial.dt. 
26 letter.dt. 
27 dissertation abstract.pt. 
28 or/24-27 
29 17 not (23 or 28) 
30 ("point of care" or "POC test*" or POCT or "near patient" or "desktop technology" or 
"office laboratory" or "set testing").ti,ab. 
31 ((test* or diagnos* or assay* or culture* or laborator* or detect* or assess* or identif* or 
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evaluat*) adj3 (rapid* or quick* or fast* or ancillary* or bedside* or decentralise* or 
"patient focus*" or portable*)).ti,ab. 
32 or/30-31 
33 29 and 32 
34 limit 33 to yr="2004 -Current" 
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A5 Health Economic Evaluation Database (HEED) Search Strategy 
 
Abstract RDT or 'POC test' Or 'POINT-OF-CARE' Or 'POINT-OF-USE' Or 'NEAR-
PATIENT' Or 'DESKTOP-TECHNOLOGY' Or POCT 
Article title RDT or 'POC test' Or 'POINT-OF-CARE' Or 'POINT-OF-USE' Or 'NEAR-
PATIENT' Or 'DESKTOP-TECHNOLOGY' Or POCT 
Abstract Rapid test within 3 
Article title Rapid test within 3 
Abstract Rapid testing within 3 
Article title Rapid testing within 3 
Abstract Rapid diagnosis within 3 
Article title Rapid diagnosis within 3 
Abstract Rapid diagnostic within 3 
Article title Rapid diagnostic within 3 
Abstract Rapid culture within 3 
Article title Rapid culture within 3 
Abstract Rapid assay within 3 
Article title Rapid assay within 3 
Abstract Rapid detect within 3 
Article title Rapid detect within 3 
Abstract Rapid identification within 3 
Article title Rapid identification within 3 
Article title Rapid identify within 3 
Abstract Rapid identify within 3 
Abstract Rapid evaluation within 3 
Article title Rapid evaluation within 3 
Abstract Fast test within 3 
Article title Fast test within 3 
Abstract Fast testing within 3 
Article title Fast testing within 3 
Abstract Fast diagnosis within 3 
Article title Fast diagnosis within 3 
Abstract Fast diagnostic within 3 
Article title Fast diagnostic within 3 
Abstract Fast culture within 3 
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Article title Fast culture within 3 
Abstract Fast assay within 3 
Article title Fast assay within 3 
Abstract Fast detect within 3 
Article title Fast detect within 3 
Abstract Fast identification within 3 
Article title Fast identification within 3 
Article title Fast identify within 3 
Abstract Fast identify within 3 
Abstract Fast evaluation within 3 
Article title Fast evaluation within 3 
Abstract Quick test within 3 
Article title Quick test within 3 
Abstract Quick testing within 3 
Article title Quick testing within 3 
Abstract Quick diagnosis within 3 
Article title Quick diagnosis within 3 
Abstract Quick diagnostic within 3 
Article title Quick diagnostic within 3 
Abstract Quick culture within 3 
Article title Quick culture within 3 
Abstract Quick assay within 3 
Article title Quick assay within 3 
Abstract Quick detect within 3 
Article title Quick detect within 3 
Abstract Quick identification within 3 
Article title Quick identification within 3 
Article title Quick identify within 3 
Abstract Quick identify within 3 
Abstract Quick evaluation within 3 
Article title Quick evaluation within 3 
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A6 NHS Economic Evaluation Database (EED) Search Strategy 
 
#1 ("point of care" or "POC test*" or POCT or "near patient" or "desktop technology" or 
"office laboratory" or "set testing"):ti,ab,kw  
#2 ((test* or diagnos* or assay* or culture* or laborator* or detect* or assess* or identif* 
or evaluat*) near/3 (rapid* or quick* or fast* or ancillary* or bedside* or decentralise* 
or "patient focus*" or portable*))  
#3 MeSH descriptor: [Point-of-Care Systems] explode all trees 
#4 #1 or #2 or #3  
#5 #4 in Economic Evaluations (Word variations have been searched) 
#6 #5 Publication Year from 2004 to 2014 (Word variations have been searched) 
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